Celltrion's Truxima leads US prescription market in February
Source ↗
👁 0
💬 0
Celltrion, a leading Korean biopharmaceutical company, said Tuesday its biosimilar Truxima, used to treat blood cancers, claimed the largest share of prescriptions in the United States in February. Truxima accounted for 35.8 percent of U.S. prescriptions in its category during the month, the company said in a press release, marking the first time a biosimilar developed by a Korean firm has led the U.S. market. Celltrion said growing demand in the U.S., the world's biggest pharmaceutical market,
Comments (0)